Clinical Trial

Study of AUBE00 in Patients With Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a first-in-human, Phase I, open-label, multicenter, multinational study, designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity, and anti-tumor activity of AUBE00 in patients with locally advanced or metastatic solid tumors.The total number of patients in this study will be approximately 90 to 130.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-06-12; most recent amendment 2026-07-16.
Trial Details
NCT Number NCT07030959
Lead Sponsor Chugai Pharmaceutical
Conditions Solid Tumors
Enrollment 130 participants
Start Date 2025-06-05
Primary Completion 2029-12-31 (estimated)
Study Completion 2029-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-20